Aimery de Gramont
Robert Mayer
MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal Cancer
REFERENCE: 4007, ASCO Annual Meeting Chicago June 1-5, 2007
AIMERY DE GRAMONT, St Antoine Hospital, Paris
COMMENT: ROBERT MAYER, Dana-Farber Cancer Institute, Boston
After six years of study the MOSAIC study of adjuvant therapy in colorectal cancer has confirmed a survival advantage for patients with stage III disease given oxaliplatin in addition to standard 5 fluoruracyl/leucovorin when compared with those who received the standard regimen alone. Oxaliplatin also improved progression free survival in patients with Stage II disease. These results were presented to the ASCO meeting by Aimery de Gramont, who discussed them with Peter Goodwin.
AIMERY DE GRAMONT, St Antoine Hospital, Paris
COMMENT: ROBERT MAYER, Dana-Farber Cancer Institute, Boston
After six years of study the MOSAIC study of adjuvant therapy in colorectal cancer has confirmed a survival advantage for patients with stage III disease given oxaliplatin in addition to standard 5 fluoruracyl/leucovorin when compared with those who received the standard regimen alone. Oxaliplatin also improved progression free survival in patients with Stage II disease. These results were presented to the ASCO meeting by Aimery de Gramont, who discussed them with Peter Goodwin.
Ronald Bukowski
Sorafenib for Patients with Advanced Refractory Renal Cell Carcinoma: TARGET Study Results
REFERENCE: ABSTRACT 5023, ASCO Annual Meeting Chicago June 1-5, 2007
RONALD BUKOWSKI, Cleveland Clinic OH
Sorafenib has been used after the failure of first line treatment among patients with advanced renal cell carcinoma. Ronald Bukowski presented findings showing a doubling of progression free survival. He talked about the study in Chicago with Peter Goodwin.
RONALD BUKOWSKI, Cleveland Clinic OH
Sorafenib has been used after the failure of first line treatment among patients with advanced renal cell carcinoma. Ronald Bukowski presented findings showing a doubling of progression free survival. He talked about the study in Chicago with Peter Goodwin.
Ezra Cohen
Axitinib: New Therapy for Thyroid Cancer?
REFERENCE: ABSTRACT 8011, ASCO Annual Meeting Chicago June 1-5, 2007
EZRA COHEN, University of Chicago
A new drug which inhibits receptors of vascular endothelial growth factor, or VEGF, has shown antitumor activity in patients with advanced thyroid cancer: possibly ending a 30-year wait for effective new therapies for this cancer. Derek Thorne heard about phase II study results from Ezra Cohen.
EZRA COHEN, University of Chicago
A new drug which inhibits receptors of vascular endothelial growth factor, or VEGF, has shown antitumor activity in patients with advanced thyroid cancer: possibly ending a 30-year wait for effective new therapies for this cancer. Derek Thorne heard about phase II study results from Ezra Cohen.
To listen this episode please go to 2007 ASCO Annual Meeting Daily News Podcasts.